Erlotinib is under clinical development by Sol-Gel Technologies and currently in Phase I for Palmoplantar Keratoderma. According to GlobalData, Phase I drugs for Palmoplantar Keratoderma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Erlotinib LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Erlotinib overview
Erlotinib is under development for the treatment of palmoplantar keratoderma, UVB-induced actinic keratosis, pachyonychia congenita (pachyonychia) and non-melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma). It is administered as gel by topical route. It targets epidermal growth factor receptor. The drug candidate is developed based on silica-based microencapsulation technology. The technology uses porous silica microcapsules to encapsulate drug substances.
Sol-Gel Technologies overview
Sol-Gel Technologies (Sol-Gel) is a dermatology company that carries out the identification, development and commercialization of investigational and generic topical drug products for the treatment of skin diseases. The company offers tretinoin and benzoyl peroxide cream, benzoyl peroxide cream, SGT-610 and SGT-210 and under the brand names TWYNEO, EPSOLAY. It treats acne vulgaris, inflammatory lesions of rosacea, gorlin syndrome, pachyonychia congenita and other rare skin indications. Sol-Gel utilizes a silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs. It operates in the US and Israel. Sol-Gel is headquartered in Ness Ziona, Israel.
For a complete picture of Erlotinib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
